Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0XJ4J
|
|||
| Drug Name |
1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 2
|
|||
| Synonyms |
PMID27321640-Compound-[3H]-44
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
JANSSEN PHARMACEUTICA NV [BE]
|
|||
| Structure |
 |
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 2A (PDE2A) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Phosphodiesterase 2A (PDE2A) | Target's Patent Info | [1] | |
| KEGG Pathway | Purine metabolism | |||
| cGMP-PKG signaling pathway | ||||
| Morphine addiction | ||||
| NetPath Pathway | TSH Signaling Pathway | |||
| Reactome | cGMP effects | |||
| G alpha (s) signalling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.